Charles Schwab Investment Management Inc Actinium Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 97,604 shares of ATNM stock, worth $156,166. This represents 0.0% of its overall portfolio holdings.
Number of Shares
97,604
Previous 72,093
35.39%
Holding current value
$156,166
Previous $90,000
74.44%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ATNM
# of Institutions
72Shares Held
8.18MCall Options Held
51.9KPut Options Held
6.2K-
Black Rock Inc. New York, NY1.88MShares$3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.57MShares$2.51 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA712KShares$1.14 Million0.0% of portfolio
-
State Street Corp Boston, MA645KShares$1.03 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA499KShares$798,8160.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $40.3M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...